title: Emerging platforms using liquid biopsy to detect EGFR mutations in lung cancer.
abstract: Advances in target therapies for lung cancer have enabled detection of gene mutations, specifically those of EGFR. Assays largely depend on the acquisition of tumor tissue biopsy, which is invasive and may not reflect the genomic profile of the tumor at treatment due to tumor heterogeneity or changes that occur during treatment through acquired resistance. Liquid biopsy, a blood test that detects evidence of cancer cells or tumor DNA, has generated considerable interest for its ability to detect EGFR mutations. However, its clinical application is limited by complicated collection methods and the need for technique-dependent platforms. Recently, simpler techniques for EGFR mutant detection in urine or saliva samples have been developed. This review focuses on advances in liquid biopsy and discusses its potential for clinical implementation in lung cancer.
authors.affiliation: a 1 Department of Internal Medicine, Institute of Clinical Medicine, National Cheng Kung University, Hospital, College of Medicine , Tainan, Taiwan.
authors.forename: Chien-Chung
authors.initials: CC
authors.lastname: Lin
authors.affiliation: a 1 Department of Internal Medicine, Institute of Clinical Medicine, National Cheng Kung University, Hospital, College of Medicine , Tainan, Taiwan.
authors.forename: Wei-Lun
authors.initials: WL
authors.lastname: Huang
authors.affiliation: b 2 UCLA - Dentistry, 73-034 CHS UCLA School of Dentistry , 10833 Le Conte Avenue, Los Angeles, California 90095, USA.
authors.forename: Fang
authors.initials: F
authors.lastname: Wei
authors.affiliation: a 1 Department of Internal Medicine, Institute of Clinical Medicine, National Cheng Kung University, Hospital, College of Medicine , Tainan, Taiwan.
authors.forename: Wu-Chou
authors.initials: WC
authors.lastname: Su
authors.affiliation: b 2 UCLA - Dentistry, 73-034 CHS UCLA School of Dentistry , 10833 Le Conte Avenue, Los Angeles, California 90095, USA.
authors.forename: David T
authors.initials: DT
authors.lastname: Wong
mesh_terms: D001826:Body Fluids / Q000737:chemistry / Q000166:cytology / Q000378:metabolism; D004273:DNA, Neoplasm / Q000097:blood; D055088:Early Detection of Cancer / Q000379:methods; D066246:ErbB Receptors / Q000235:genetics*; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000235:genetics* / Q000628:therapy; D025202:Molecular Diagnostic Techniques / Q000379:methods; D009154:Mutation; D009360:Neoplastic Cells, Circulating / Q000378:metabolism / Q000473:pathology; D011379:Prognosis; D016896:Treatment Outcome
chemical_list: D004273:DNA, Neoplasm; D066246:ErbB Receptors
keywords: epidermal growth factor receptor; liquid biopsy; lung cancer; saliva; target therapy